A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 31 May 2016
At a glance
- Drugs GNbAC1 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors GeNeuro
- 21 Apr 2016 Pharmacokinetic and safety data (n=21) presented at the 68th Annual Meeting of the American Academy of Neurology.
- 19 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jun 2015 New trial record